{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104956",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104956",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for clopidogrel and CYP2C19",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA449053",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA449053",
    "name" : "clopidogrel"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA124",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA124",
    "symbol" : "CYP2C19",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 19"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>The Dutch Pharmacogenetics Working Group Guideline for clopidogrel recommends to consider an alternative drug for CYP2C19 poor or intermediate metabolizers, because of increased risk for reduced response to clopidogrel. Prasugrel might be associated with an increased bleeding risk compared to clopidogrel.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clopidogrel based on the <em>CYP2C19</em> genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  For the  <em>CYP2C19</em> PM and IM phenotype they conclude an increased risk for reduced response to clopidogrel and recommend to consider an alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> <em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3) </td><td> Increased risk for reduced response to clopidogrel. Consider alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Clinical effect (statistically significant difference): death; arrhythmia; unanticipated myelosuppression </td></tr><tr><td> <em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3) </td><td> Increased risk for reduced response to clopidogrel. Consider alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Clinical effect (statistically significant difference): death; arrhythmia; unanticipated myelosuppression </td></tr><tr><td> <em>CYP2C19</em> UM (*17/*17) </td><td> None </td><td> Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 <br/>Kinetic effect (statistically significant difference) </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>#wherever one or more of the \"good quality\" criteria was missing, the quality of the study was considered to be \"moderate\"</li></ul>"
}